Trial Profile
A Phase 2 Randomized, Open Label Clinical Trial in High Risk Percutaneous Coronary Intervention (PCI) Patients Receiving Standard Antithrombotic Treatment Plus Either ALX-0081 or GPIIb/IIIa Inhibitor (ReoPro) Over a Period of 24 Hours.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Caplacizumab (Primary) ; Abciximab
- Indications Angina pectoris; Coronary stent thrombosis; Myocardial infarction; Unstable angina pectoris
- Focus Adverse reactions
- Sponsors Ablynx
- 18 Jul 2012 Company added in the association field as reported by EudraCT.
- 14 Nov 2011 Status changed from active, no longer recruiting to completed.
- 02 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.